<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">20974282</PMID><DateCompleted><Year>2011</Year><Month>06</Month><Day>07</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1878-5832</ISSN><JournalIssue CitedMedium="Internet"><Volume>15</Volume><Issue>23-24</Issue><PubDate><Year>2010</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Drug discovery today</Title><ISOAbbreviation>Drug Discov Today</ISOAbbreviation></Journal><ArticleTitle>Developments towards antiviral therapies against enterovirus 71.</ArticleTitle><Pagination><StartPage>1041</StartPage><EndPage>1051</EndPage><MedlinePgn>1041-51</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.drudis.2010.10.008</ELocationID><Abstract><AbstractText>Enterovirus 71 (EV71) has emerged as a clinically important neurotropic virus that can cause acute flaccid paralysis and encephalitis, leading to cardiopulmonary failure and death. Recurring outbreaks of EV71 have been reported in several countries. The current lack of approved anti-EV71 therapy has prompted intense research into antiviral development. Several strategies--ranging from target-based chemical design to compound library screenings--have been employed, while others revisited compound series generated from antiviral developments against poliovirus and human rhinoviruses. These efforts have given rise to a diversity of antiviral candidates that include small molecules and non-conventional nucleic-acid-based strategies. This review aims to highlight candidates with potential for further clinical development based on their putative modes of action.</AbstractText><CopyrightInformation>Copyright &#xa9; 2010 Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Kan X</ForeName><Initials>KX</Initials><AffiliationInfo><Affiliation>Department of Microbiology, Yong Loo Lin School of Medicine, National University Health System, 5 Science Drive 2, National University of Singapore, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ng</LastName><ForeName>Mary M-L</ForeName><Initials>MM</Initials></Author><Author ValidYN="Y"><LastName>Chu</LastName><ForeName>Justin J H</ForeName><Initials>JJ</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2010</Year><Month>10</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Drug Discov Today</MedlineTA><NlmUniqueID>9604391</NlmUniqueID><ISSNLinking>1359-6446</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020805" MajorTopicYN="N">Central Nervous System Viral Diseases</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D029821" MajorTopicYN="N">Enterovirus A, Human</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D030015" MajorTopicYN="N">Enterovirus C, Human</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004769" MajorTopicYN="N">Enterovirus Infections</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2010</Year><Month>6</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2010</Year><Month>9</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2010</Year><Month>10</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>10</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>10</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>6</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2010</Year><Month>10</Month><Day>23</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20974282</ArticleId><ArticleId IdType="pmc">PMC7108380</ArticleId><ArticleId IdType="doi">10.1016/j.drudis.2010.10.008</ArticleId><ArticleId IdType="pii">S1359-6446(10)00778-6</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Oberste M.S. Molecular evolution of the human enteroviruses: correlation of serotype with VP1 sequence and application to picornavirus classification. J. Virol. 1999;73:1941&#x2013;1948.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC104435</ArticleId><ArticleId IdType="pubmed">9971773</ArticleId></ArticleIdList></Reference><Reference><Citation>CDC Progress toward interruption of wild poliovirus transmission &#x2013; worldwide, 2008. Morb. Mortal. Wkly. Rep. 2009;58:308&#x2013;312.</Citation><ArticleIdList><ArticleId IdType="pubmed">19343011</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt N.J. An apparently new enterovirus isolated from patients with disease of the central nervous system. J. Infect. Dis. 1974;129:304&#x2013;309.</Citation><ArticleIdList><ArticleId IdType="pubmed">4361245</ArticleId></ArticleIdList></Reference><Reference><Citation>McMinn P.C. An overview of the evolution of enterovirus 71 and its clinical and public health significance. FEMS Microbiol. Rev. 2002;26:91&#x2013;107.</Citation><ArticleIdList><ArticleId IdType="pubmed">12007645</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin T.Y. The 1998 enterovirus 71 outbreak in Taiwan: pathogenesis and management. Clin. Infect. Dis. 2002;34(Suppl. 2):S52&#x2013;S57.</Citation><ArticleIdList><ArticleId IdType="pubmed">11938497</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang L.Y. Neurodevelopment and cognition in children after enterovirus 71 infection. N. Engl. J. Med. 2007;356:1226&#x2013;1234.</Citation><ArticleIdList><ArticleId IdType="pubmed">17377160</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang J.N. Critical management in patients with severe enterovirus 71 infection. Pediatr. Int. 2006;48:250&#x2013;256.</Citation><ArticleIdList><ArticleId IdType="pubmed">16732789</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsiung G.D., Wang J.R. Enterovirus infections with special reference to enterovirus 71. J. Microbiol. Immunol. Infect. 2000;33:1&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">10806956</ArticleId></ArticleIdList></Reference><Reference><Citation>Shih S.R. Selective human enterovirus and rhinovirus inhibitors: an overview of capsid-binding and protease-inhibiting molecules. Med. Res. Rev. 2004;24:449&#x2013;474.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7168432</ArticleId><ArticleId IdType="pubmed">15170592</ArticleId></ArticleIdList></Reference><Reference><Citation>De Palma A.M. Selective inhibitors of picornavirus replication. Med. Res. Rev. 2008;28:823&#x2013;884.</Citation><ArticleIdList><ArticleId IdType="pubmed">18381747</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen T.C. Development of antiviral agents for enteroviruses. J. Antimicrob. Chemother. 2008;62:1169&#x2013;1173.</Citation><ArticleIdList><ArticleId IdType="pubmed">18931391</ArticleId></ArticleIdList></Reference><Reference><Citation>Patick A.K., Potts K.E. Protease inhibitors as antiviral agents. Clin. Microbiol. Rev. 1998;11:614&#x2013;627.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC88900</ArticleId><ArticleId IdType="pubmed">9767059</ArticleId></ArticleIdList></Reference><Reference><Citation>Diana G.D. Inhibitors of picornavirus uncoating as antiviral agents. Pharmacol. Ther. 1985;29:287&#x2013;297.</Citation><ArticleIdList><ArticleId IdType="pubmed">3014575</ArticleId></ArticleIdList></Reference><Reference><Citation>Barnard D.L. Current status of anti-picornavirus therapies. Curr. Pharm. Des. 2006;12:1379&#x2013;1390.</Citation><ArticleIdList><ArticleId IdType="pubmed">16611122</ArticleId></ArticleIdList></Reference><Reference><Citation>Li C. The efficacy of viral capsid inhibitors in human enterovirus infection and associated diseases. Curr. Med. Chem. 2007;14:847&#x2013;856.</Citation><ArticleIdList><ArticleId IdType="pubmed">17430140</ArticleId></ArticleIdList></Reference><Reference><Citation>Bedard K.M., Semler B.L. Regulation of picornavirus gene expression. Microbes Infect. 2004;6:702&#x2013;713.</Citation><ArticleIdList><ArticleId IdType="pubmed">15158778</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamayoshi S. Scavenger receptor B2 is a cellular receptor for enterovirus 71. Nat. Med. 2009;15:798&#x2013;801.</Citation><ArticleIdList><ArticleId IdType="pubmed">19543282</ArticleId></ArticleIdList></Reference><Reference><Citation>Laszik Z. P-selectin glycoprotein ligand-1 is broadly expressed in cells of myeloid, lymphoid, and dendritic lineage and in some nonhematopoietic cells. Blood. 1996;88:3010&#x2013;3021.</Citation><ArticleIdList><ArticleId IdType="pubmed">8874199</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishimura Y. Human P-selectin glycoprotein ligand-1 is a functional receptor for enterovirus 71. Nat. Med. 2009;15:794&#x2013;797.</Citation><ArticleIdList><ArticleId IdType="pubmed">19543284</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang B. Sialylated glycans as receptor and inhibitor of enterovirus 71 infection to DLD-1 intestinal cells. Virol. J. 2009;6:141.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2751754</ArticleId><ArticleId IdType="pubmed">19751532</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin Y.W. Enterovirus 71 infection of human dendritic cells. Exp. Biol. Med. (Maywood) 2009;234:1166&#x2013;1173.</Citation><ArticleIdList><ArticleId IdType="pubmed">19596831</ArticleId></ArticleIdList></Reference><Reference><Citation>Smyth M.S., Martin J.H. Picornavirus uncoating. Mol. Pathol. 2002;55:214&#x2013;219.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1187181</ArticleId><ArticleId IdType="pubmed">12147709</ArticleId></ArticleIdList></Reference><Reference><Citation>Pevear D.C. Activity of pleconaril against enteroviruses. Antimicrob. Agents Chemother. 1999;43:2109&#x2013;2115.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC89431</ArticleId><ArticleId IdType="pubmed">10471549</ArticleId></ArticleIdList></Reference><Reference><Citation>Buontempo P.J. SCH 48973: a potent, broad-spectrum, antienterovirus compound. Antimicrob. Agents Chemother. 1997;41:1220&#x2013;1225.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC163890</ArticleId><ArticleId IdType="pubmed">9174174</ArticleId></ArticleIdList></Reference><Reference><Citation>Andries K. In vitro activity of pirodavir (R 77975), a substituted phenoxy-pyridazinamine with broad-spectrum antipicornaviral activity. Antimicrob. Agents Chemother. 1992;36:100&#x2013;107.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC189235</ArticleId><ArticleId IdType="pubmed">1317142</ArticleId></ArticleIdList></Reference><Reference><Citation>Shia K.S. Design, synthesis, and structure&#x2013;activity relationship of pyridyl imidazolidinones: a novel class of potent and selective human enterovirus 71 inhibitors. J. Med. Chem. 2002;45:1644&#x2013;1655.</Citation><ArticleIdList><ArticleId IdType="pubmed">11931618</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen T.C. Antiviral activity of pyridyl imidazolidinones against enterovirus 71 variants. J. Biomed. Sci. 2008;15:291&#x2013;300.</Citation><ArticleIdList><ArticleId IdType="pubmed">18196474</ArticleId></ArticleIdList></Reference><Reference><Citation>Watson K.G. An orally bioavailable oxime ether capsid binder with potent activity against human rhinovirus. J. Med. Chem. 2003;46:3181&#x2013;3184.</Citation><ArticleIdList><ArticleId IdType="pubmed">12852746</ArticleId></ArticleIdList></Reference><Reference><Citation>Barnard D.L. In vitro activity of expanded-spectrum pyridazinyl oxime ethers related to pirodavir: novel capsid-binding inhibitors with potent antipicornavirus activity. Antimicrob. Agents Chemother. 2004;48:1766&#x2013;1772.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC400527</ArticleId><ArticleId IdType="pubmed">15105133</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin T.Y. Lactoferrin inhibits enterovirus 71 infection of human embryonal rhabdomyosarcoma cells in vitro. J. Infect. Dis. 2002;186:1161&#x2013;1164.</Citation><ArticleIdList><ArticleId IdType="pubmed">12355368</ArticleId></ArticleIdList></Reference><Reference><Citation>Weng T.Y. Lactoferrin inhibits enterovirus 71 infection by binding to VP1 protein and host cells. Antiviral Res. 2005;67:31&#x2013;37.</Citation><ArticleIdList><ArticleId IdType="pubmed">15916817</ArticleId></ArticleIdList></Reference><Reference><Citation>Bugatti A. Heparin-mimicking sulfonic acid polymers as multitarget inhibitors of human immunodeficiency virus type 1 Tat and gp120 proteins. Antimicrob. Agents Chemother. 2007;51:2337&#x2013;2345.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1913280</ArticleId><ArticleId IdType="pubmed">17452490</ArticleId></ArticleIdList></Reference><Reference><Citation>Arita M. Characterization of pharmacologically active compounds that inhibit poliovirus and enterovirus 71 infectivity. J. Gen. Virol. 2008;89:2518&#x2013;2530.</Citation><ArticleIdList><ArticleId IdType="pubmed">18796721</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y.J. Amantadine as a regulator of internal ribosome entry site. Acta Pharmacol. Sin. 2008;29:1327&#x2013;1333.</Citation><ArticleIdList><ArticleId IdType="pubmed">18954527</ArticleId></ArticleIdList></Reference><Reference><Citation>Roehr B. Fomivirsen approved for CMV retinitis. J. Int. Assoc. Phys. AIDS Care. 1998;4:14&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pubmed">11365956</ArticleId></ArticleIdList></Reference><Reference><Citation>Haasnoot J. RNA interference against viruses: strike and counterstrike. Nat. Biotechnol. 2007;25:1435&#x2013;1443.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7096910</ArticleId><ArticleId IdType="pubmed">18066040</ArticleId></ArticleIdList></Reference><Reference><Citation>Sim A.C. RNA interference against enterovirus 71 infection. Virology. 2005;341:72&#x2013;79.</Citation><ArticleIdList><ArticleId IdType="pubmed">16083932</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu Z. Identification of small interfering RNAs which inhibit the replication of several enterovirus 71 strains in China. J. Virol. Methods. 2009;159:233&#x2013;238.</Citation><ArticleIdList><ArticleId IdType="pubmed">19490979</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu W.W. Selective inhibition of enterovirus 71 replication by short hairpin RNAs. Biochem. Biophys. Res. Commun. 2004;325:494&#x2013;499.</Citation><ArticleIdList><ArticleId IdType="pubmed">15530419</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan E.L. Inhibition of enterovirus 71 in virus-infected mice by RNA interference. Mol. Ther. 2007;15:1931&#x2013;1938.</Citation><ArticleIdList><ArticleId IdType="pubmed">17712333</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuo R.L. Infection with enterovirus 71 or expression of its 2A protease induces apoptotic cell death. J. Gen. Virol. 2002;83:1367&#x2013;1376.</Citation><ArticleIdList><ArticleId IdType="pubmed">12029152</ArticleId></ArticleIdList></Reference><Reference><Citation>Weng K.F. Enterovirus 71 3C protease cleaves a novel target CstF-64 and inhibits cellular polyadenylation. PLoS Pathog. 2009;5:e1000593.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2742901</ArticleId><ArticleId IdType="pubmed">19779565</ArticleId></ArticleIdList></Reference><Reference><Citation>Li M.L. The 3C protease activity of enterovirus 71 induces human neural cell apoptosis. Virology. 2002;293:386&#x2013;395.</Citation><ArticleIdList><ArticleId IdType="pubmed">11886259</ArticleId></ArticleIdList></Reference><Reference><Citation>Patick A.K. Rhinovirus chemotherapy. Antiviral Res. 2006;71:391&#x2013;396.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7132408</ArticleId><ArticleId IdType="pubmed">16675037</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuo C.J. Design, synthesis, and evaluation of 3C protease inhibitors as anti-enterovirus 71 agents. Bioorg. Med. Chem. 2008;16:7388&#x2013;7398.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7125518</ArticleId><ArticleId IdType="pubmed">18583140</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsai M.T. Real-time monitoring of human enterovirus (HEV)-infected cells and anti-HEV 3C protease potency by fluorescence resonance energy transfer. Antimicrob. Agents Chemother. 2009;53:748&#x2013;755.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2630644</ArticleId><ArticleId IdType="pubmed">19015331</ArticleId></ArticleIdList></Reference><Reference><Citation>Patick A.K. In vitro antiviral activity and single-dose pharmacokinetics in humans of a novel, orally bioavailable inhibitor of human rhinovirus 3C protease. Antimicrob. Agents Chemother. 2005;49:2267&#x2013;2275.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1140523</ArticleId><ArticleId IdType="pubmed">15917520</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodriguez P.L., Carrasco L. Poliovirus protein 2C has ATPase and GTPase activities. J. Biol. Chem. 1993;268:8105&#x2013;8110.</Citation><ArticleIdList><ArticleId IdType="pubmed">8385138</ArticleId></ArticleIdList></Reference><Reference><Citation>Banerjee R. Poliovirus-encoded 2C polypeptide specifically binds to the 3&#x2032;-terminal sequences of viral negative-strand RNA. J. Virol. 1997;71:9570&#x2013;9578.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC230265</ArticleId><ArticleId IdType="pubmed">9371621</ArticleId></ArticleIdList></Reference><Reference><Citation>Vance L.M. Poliovirus 2C region functions during encapsidation of viral RNA. J. Virol. 1997;71:8759&#x2013;8765.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC192341</ArticleId><ArticleId IdType="pubmed">9343235</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang W.F. Reticulon 3 binds the 2C protein of enterovirus 71 and is required for viral replication. J. Biol. Chem. 2007;282:5888&#x2013;5898.</Citation><ArticleIdList><ArticleId IdType="pubmed">17182608</ArticleId></ArticleIdList></Reference><Reference><Citation>Belov G.A., Ehrenfeld E. Involvement of cellular membrane traffic proteins in poliovirus replication. Cell Cycle. 2007;6:36&#x2013;38.</Citation><ArticleIdList><ArticleId IdType="pubmed">17245115</ArticleId></ArticleIdList></Reference><Reference><Citation>Paul A.V. Studies with poliovirus polymerase 3Dpol. Stimulation of poly(U) synthesis in vitro by purified poliovirus protein 3AB. J. Biol. Chem. 1994;269:29173&#x2013;29181.</Citation><ArticleIdList><ArticleId IdType="pubmed">7961883</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiang W. Molecular dissection of the multifunctional poliovirus RNA-binding protein 3AB. RNA. 1995;1:892&#x2013;904.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1369338</ArticleId><ArticleId IdType="pubmed">8548654</ArticleId></ArticleIdList></Reference><Reference><Citation>Heinz B.A., Vance L.M. Sequence determinants of 3A-mediated resistance to enviroxime in rhinoviruses and enteroviruses. J. Virol. 1996;70:4854&#x2013;4857.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC190432</ArticleId><ArticleId IdType="pubmed">8676522</ArticleId></ArticleIdList></Reference><Reference><Citation>De Palma A.M. Potential use of antiviral agents in polio eradication. Emerg. Infect. Dis. 2008;14:545&#x2013;551.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2570929</ArticleId><ArticleId IdType="pubmed">18394270</ArticleId></ArticleIdList></Reference><Reference><Citation>De Palma A.M. Mutations in the nonstructural protein 3A confer resistance to the novel enterovirus replication inhibitor TTP-8307. Antimicrob. Agents Chemother. 2009;53:1850&#x2013;1857.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2681499</ArticleId><ArticleId IdType="pubmed">19237651</ArticleId></ArticleIdList></Reference><Reference><Citation>Phillpotts R.J. Therapeutic activity of enviroxime against rhinovirus infection in volunteers. Antimicrob. Agents Chemother. 1983;23:671&#x2013;675.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC184785</ArticleId><ArticleId IdType="pubmed">6870216</ArticleId></ArticleIdList></Reference><Reference><Citation>Victor F. Synthesis, antiviral activity, and biological properties of vinylacetylene analogs of enviroxime. J. Med. Chem. 1997;40:1511&#x2013;1518.</Citation><ArticleIdList><ArticleId IdType="pubmed">9154972</ArticleId></ArticleIdList></Reference><Reference><Citation>Arita M. Cellular kinase inhibitors that suppress enterovirus replication have a conserved target in viral protein 3A similar to that of enviroxime. J. Gen. Virol. 2009;90:1869&#x2013;1879.</Citation><ArticleIdList><ArticleId IdType="pubmed">19439558</ArticleId></ArticleIdList></Reference><Reference><Citation>Paul A.V. Protein-primed RNA synthesis by purified poliovirus RNA polymerase. Nature. 1998;393:280&#x2013;284.</Citation><ArticleIdList><ArticleId IdType="pubmed">9607767</ArticleId></ArticleIdList></Reference><Reference><Citation>Ypma-Wong M.F. Protein 3CD is the major poliovirus proteinase responsible for cleavage of the P1 capsid precursor. Virology. 1988;166:265&#x2013;270.</Citation><ArticleIdList><ArticleId IdType="pubmed">2842953</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiang W. Interaction between the 5&#x2032;-terminal cloverleaf and 3AB/3CDpro of poliovirus is essential for RNA replication. J. Virol. 1995;69:3658&#x2013;3667.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC189081</ArticleId><ArticleId IdType="pubmed">7745714</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen T.C. Novel antiviral agent DTriP-22 targets RNA-dependent RNA polymerase of enterovirus 71. Antimicrob. Agents Chemother. 2009;53:2740&#x2013;2747.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2704669</ArticleId><ArticleId IdType="pubmed">19414569</ArticleId></ArticleIdList></Reference><Reference><Citation>Hung H.C. Inhibition of enterovirus 71 replication and the viral 3D polymerase by aurintricarboxylic acid. J. Antimicrob. Chemother. 2010;65:676&#x2013;683.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7110181</ArticleId><ArticleId IdType="pubmed">20089540</ArticleId></ArticleIdList></Reference><Reference><Citation>de Ledinghen V. Daily or three times a week interferon alfa-2b in combination with ribavirin or interferon alone for the treatment of patients with chronic hepatitis C. J. Hepatol. 2002;36:672&#x2013;680.</Citation><ArticleIdList><ArticleId IdType="pubmed">11983451</ArticleId></ArticleIdList></Reference><Reference><Citation>Wyde P.R. Respiratory syncytial virus (RSV) disease and prospects for its control. Antiviral Res. 1998;39:63&#x2013;79.</Citation><ArticleIdList><ArticleId IdType="pubmed">9806484</ArticleId></ArticleIdList></Reference><Reference><Citation>Crotty S., Andino R. Implications of high RNA virus mutation rates: lethal mutagenesis and the antiviral drug ribavirin. Microbes Infect. 2002;4:1301&#x2013;1307.</Citation><ArticleIdList><ArticleId IdType="pubmed">12443894</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Z.H. Ribavirin reduces mortality in enterovirus 71-infected mice by decreasing viral replication. J. Infect. Dis. 2008;197:854&#x2013;857.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7109938</ArticleId><ArticleId IdType="pubmed">18279075</ArticleId></ArticleIdList></Reference><Reference><Citation>Ho H.Y. Antiviral effect of epigallocatechin gallate on enterovirus 71. J. Agric. Food Chem. 2009;57:6140&#x2013;6147.</Citation><ArticleIdList><ArticleId IdType="pubmed">19537794</ArticleId></ArticleIdList></Reference><Reference><Citation>Ho H.Y. Glucose-6-phosphate dehydrogenase deficiency enhances enterovirus 71 infection. J. Gen. Virol. 2008;89:2080&#x2013;2089.</Citation><ArticleIdList><ArticleId IdType="pubmed">18753216</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu M.L. Type I interferons protect mice against enterovirus 71 infection. J. Gen. Virol. 2005;86:3263&#x2013;3269.</Citation><ArticleIdList><ArticleId IdType="pubmed">16298971</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin C.W. Aloe-emodin is an interferon-inducing agent with antiviral activity against Japanese encephalitis virus and enterovirus 71. Int. J. Antimicrob. Agents. 2008;32:355&#x2013;359.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7126984</ArticleId><ArticleId IdType="pubmed">18701259</ArticleId></ArticleIdList></Reference><Reference><Citation>Shih S.R. Viral protein synthesis is required for enterovirus 71 to induce apoptosis in human glioblastoma cells. J. Neurovirol. 2008;14:53&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pubmed">18300075</ArticleId></ArticleIdList></Reference><Reference><Citation>Vincent M.J. Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virol. J. 2005;2:69.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1232869</ArticleId><ArticleId IdType="pubmed">16115318</ArticleId></ArticleIdList></Reference><Reference><Citation>Savarino A. Anti-HIV effects of chloroquine: inhibition of viral particle glycosylation and synergism with protease inhibitors. J. Acquir. Immune Defic. Syndr. 2004;35:223&#x2013;232.</Citation><ArticleIdList><ArticleId IdType="pubmed">15076236</ArticleId></ArticleIdList></Reference><Reference><Citation>Shih S.R. Inhibition of enterovirus 71-induced apoptosis by allophycocyanin isolated from a blue-green alga Spirulina platensis. J. Med. Virol. 2003;70:119&#x2013;125.</Citation><ArticleIdList><ArticleId IdType="pubmed">12629652</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi H.J. Antiviral activity of raoulic acid from Raoulia australis against picornaviruses. Phytomedicine. 2009;16:35&#x2013;39.</Citation><ArticleIdList><ArticleId IdType="pubmed">19097770</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiang L.C. Antiviral activities of extracts and selected pure constituents of Ocimum basilicum. Clin. Exp. Pharmacol. Physiol. 2005;32:811&#x2013;816.</Citation><ArticleIdList><ArticleId IdType="pubmed">16173941</ArticleId></ArticleIdList></Reference><Reference><Citation>Weng K.F. Neural pathogenesis of enterovirus 71 infection. Microbes Infect. 2010;12:505&#x2013;510.</Citation><ArticleIdList><ArticleId IdType="pubmed">20348010</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen C.S. Retrograde axonal transport: a major transmission route of enterovirus 71 in mice. J. Virol. 2007;81:8996&#x2013;9003.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1951457</ArticleId><ArticleId IdType="pubmed">17567704</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan K.P. Epidemic hand, foot and mouth disease caused by human enterovirus 71, Singapore. Emerg. Infect. Dis. 2003;9:78&#x2013;85.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2873753</ArticleId><ArticleId IdType="pubmed">12533285</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>